Can Ozempic Keep Families Together? Pennsylvania Tests GLP-1 Drugs to Prevent Foster Care Removals

Allegheny County, Pennsylvania, is launching an unprecedented experiment that could reshape how America addresses both addiction and child welfare. The county's Department of Human Services plans to pay individuals with substance use disorder to take GLP-1 medications like Ozempic and Wegovy — drugs originally developed for diabetes and weight loss — in hopes of reducing drug cravings and preventing children from entering foster care.

The initiative, currently under review by philanthropic foundations including Arnold Ventures, represents a novel application of emerging research showing that GLP-1 receptor agonists may reduce cravings not just for food, but for alcohol, opioids, cocaine, and methamphetamines. More than a third of the people eligible for the project have had "screened in" referrals to child welfare, meaning someone reported them for allegedly abusing or neglecting a child and the department found the report plausible enough to investigate.

The Scope of the Crisis

The connection between substance use and child welfare involvement is stark. Up to 90 percent of families involved with the child welfare system are affected by substance use disorders. Across the country, the drug crisis fuels child abuse and neglect through pediatric poisonings, children deprived of food or medical care because their parents are impaired, and kids exposed to dangerous individuals as parents seek drugs.

These factors contribute to more than 2,000 child maltreatment fatalities each year. The Trump administration recently announced that states could use Title IV-E child welfare funding for drug treatment programs for parents, acknowledging that addressing parental substance use is essential to keeping families together.

But offering programs is not enough to get parents to stop using, as many jurisdictions are discovering. A 2021 Washington state law offered parents voluntary drug treatment and mental health services. More than two-thirds refused. Washington, D.C., and Illinois have recently launched programs giving parents in the child welfare system unrestricted cash, but advocates worry that handing cash to those with substance use disorder may fund continued drug use rather than improved parenting.

How GLP-1s Might Break the Cycle

GLP-1 drugs work by mimicking a hormone that regulates appetite and blood sugar, but research suggests their effects extend to the brain's reward system. In April 2026, NIDA Director Nora Volkow and colleagues reviewed reports showing lower rates of alcohol-related events, reduced opioid overdose risk, and associations extending to nicotine, cocaine, cannabis, and other substances among people taking these medications.

The mechanism appears to involve the mesolimbic dopamine system — the same neural pathway hijacked by addictive substances. By modulating reward signaling, GLP-1s may reduce the intensity of cravings without producing the euphoria or dependence associated with traditional addiction medications.

This pharmacological profile offers several advantages for the child welfare population. Unlike methadone, GLP-1s are not controlled substances. There is no risk of overdose, and they do not require the same levels of supervision. The drugs also have broad health benefits beyond addiction treatment, including weight loss, reduced diabetes risk, and potentially lower dementia risk — factors that may increase willingness to participate among people who might reject traditional addiction treatment.

The Allegheny County Model

The GLP-1 project builds on a precursor program launched earlier this year and funded by Arnold Ventures. That initiative pays up to 500 people to stay off drugs and alcohol using more traditional medications, including injections of Sublocade and Vivitrol to treat opioid and alcohol addiction. Participants receive incentives starting at $2 per day and other payments in exchange for adhering to treatment.

About a third of this group also had screened-in child welfare referrals, creating a natural bridge to the GLP-1 study. The county is applying contingency management — paying small amounts to stay clean — in a real-world context, supported by research showing this approach has a promising record.

"Child welfare can't be naive," said Alex Jutca, interim director of the Allegheny County Department of Human Services. "I read cases where we are a little bit too credulous about what's going on in these homes. If you have a parent in the throes of addiction and they're not willing to take steps to fix it... Even if they are willing, it's still red alert."

Removing children may sometimes be warranted and may even help, Jutca acknowledges, but "what we do with these folks with respect to support is wildly inadequate." Sending text messages every two weeks to remind people about treatment programs is not sufficient. "We can't think about these things episodically."

Long-Acting Advantages

The Allegheny program emphasizes long-acting medications — whether weekly injections of Wegovy or monthly injections of Sublocade — over daily dosing regimens. Stephen Higgins, director of the Vermont Center on Behavior and Health, explains that "in populations with problems where adherence is a problem, the fewer times you need to get them to adhere the better the chances of success."

A recent experiment comparing outcomes of people released from jails in Maine found that those who went on long-acting medication were more likely to remain drug-free and were less likely to die from an overdose in the year following release. The same logic applies to parents at risk of losing their children: missed doses of daily medication can lead to relapse, which can lead to child removal.

GLP-1s fit this model well. Semaglutide, the active ingredient in Ozempic and Wegovy, is typically administered weekly. This reduces the logistical burden on participants and the risk of treatment interruption due to missed appointments.

Broader Implications

If successful, the Allegheny County experiment could provide a template for other jurisdictions struggling with the intersection of addiction and child welfare. The approach combines several evidence-based elements: medication-assisted treatment, contingency management, and long-acting formulations. The innovation is applying these tools to a population — parents at risk of child welfare involvement — that has historically been difficult to engage in treatment.

The timing is significant. The Trump administration's recent executive order on psychedelics and the FDA's fast-tracking of psychedelic therapies for mental health and substance use disorders signal growing federal interest in novel pharmacological approaches to addiction. GLP-1s, already approved for other indications and widely available, could represent a more immediately scalable option.

However, significant questions remain. The research on GLP-1s for addiction is still emerging, with most studies observational rather than randomized controlled trials. It is unclear whether the effects on substance use are as robust as the effects on appetite, or whether they persist over the long term. Side effects, while generally mild, can include nausea and gastrointestinal distress that might affect adherence.

Cost and access also pose challenges. GLP-1 medications are expensive, often costing over $1,000 per month without insurance coverage. While the Allegheny program plans to use philanthropic funding, scaling this approach would require addressing reimbursement and coverage gaps. As of January 2026, just 13 states covered GLP-1s for weight management through Medicaid, down from 16 states in 2025.

What Success Would Look Like

For Higgins, the Vermont researcher advising on the project, success means keeping families together. "These psychiatric conditions and drug addiction wreak havoc in families. Getting people to take these meds will keep families together."

The metrics will be concrete: reduction in screened-in child welfare referrals among participants, decrease in foster care placements, improvement in substance use outcomes, and cost savings from avoided foster care expenditures. If the program demonstrates even modest improvements on these measures, it could catalyze similar initiatives nationwide.

The Allegheny County experiment represents a pragmatic, evidence-informed approach to one of America's most intractable social problems. Rather than choosing between parental rights and child safety, between harm reduction and abstinence, the program attempts to address the biological drivers of addiction while providing the structural support families need to stay together. Whether this synthesis will work in practice remains to be seen, but the urgency of the crisis demands innovative solutions.